XERS Insider Trading
Insider Ownership Percentage: 4.56%
Insider Buying (Last 12 Months): $10,155.45
Insider Selling (Last 12 Months): $217,200.00
Xeris Biopharma Insider Trading History Chart
This chart shows the insider buying and selling history at Xeris Biopharma by year and by quarter.
Skip ChartChart Data in Insider Trading History Table
Xeris Biopharma Share Price & Price History
Current Price: $4.41
Price Change: ▼ Price Decrease of -0.47 (-9.63%)
As of 04/4/2025 05:00 PM ET
Xeris Biopharma Insider Trading History
Xeris Biopharma Institutional Trading History
Data available starting January 2016
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
Read More on Xeris Biopharma
Volume
3,865,163 shs
Average Volume
1,806,498 shs
Market Capitalization
$678.88 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.37
Who are the company insiders with the largest holdings of Xeris Biopharma?